Immune-Onc Therapeutics
Palo Alto, US · Founded 2015 · Delaware corporation · 3 known investors
Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
Founders & leadership
Immune-Onc Therapeutics was founded in 2015 by Xiaoling Charlene Liao.
XC
Xiaoling Charlene LiaoFounder
Board
GY
Guo-Liang YuBoard director
LL
Liqun LuoBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$7M disclosed across 1 round · 2016
▶$7MraisedSep 2016 · 14 investors · BiotechnologyRule 506(b)
▶$7MraisedSep 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Xiaoling Charlene LiaoExecutive Officer, Director
- Guo-Liang YuDirector
- Liqun LuoDirector
- Offering amount
- $7M
- Amount sold
- $7M
- Minimum investment
- $1
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Inimmune50 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Immuneering41 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immunome40 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Immunomic Therapeutics37 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Immunai34 shared keywordsImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Immunocore32 shared keywordsImmunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.
Companies competing with Immune-Onc Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.1M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Immune-Onc Therapeutics do?
- Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
- Who founded Immune-Onc Therapeutics?
- Immune-Onc Therapeutics was founded by Xiaoling Charlene Liao in 2015.
- Who are Immune-Onc Therapeutics's investors?
- Immune-Onc Therapeutics's investors include Northern Light Venture Capital, ShangBay Capital LLC, Vivo Capital.
- How much funding has Immune-Onc Therapeutics raised?
- Immune-Onc Therapeutics has disclosed $7M raised across 1 round.
- Where is Immune-Onc Therapeutics headquartered?
- Immune-Onc Therapeutics is headquartered in Palo Alto, US.